Medlock K L, Branham W S, Sheehan D M
Department of Health and Human Services, Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas 72079-9502, USA.
Biol Reprod. 1997 May;56(5):1239-44. doi: 10.1095/biolreprod56.5.1239.
In the developing rodent uterus, the estrogen agonist activity of triphenylethylene antiestrogens such as tamoxifen alters uterine luminal epithelium morphology and inhibits uterine gland genesis. We examined uterine growth and differentiation in female offspring from date-mated Sprague-Dawley rats given the structurally related antiestrogen, toremifene, by s.c. injection in 10 microl of sesame oil on postnatal days (PND) 1-5, 10-14, or 20-24. Toremifene given on PND 10-14, a period of rapid uterine gland differentiation, caused a dose-related increase in uterine weight, tripled luminal epithelium cell height, and completely inhibited uterine gland development on PND 14 at doses of 10 microg or higher. Based on this dose-response analysis, a 10-microg dose of toremifene was chosen to assess uterine development after neonatal exposure (PND 1-5). Uterine weights and luminal epithelium cell heights were significantly increased by toremifene on PND 5 but returned to control levels by PND 26. Uterine gland numbers were reduced to 50% those of controls on PND 26. Dose-related uterine weight and luminal epithelium cell height increases were also observed in rats given toremifene on PND 20-24. This estrogen agonist activity of toremifene, revealed primarily in the uterine luminal epithelium, indicates that toremifene is developmentally toxic.
在发育中的啮齿动物子宫中,他莫昔芬等三苯乙烯类抗雌激素的雌激素激动剂活性会改变子宫腔上皮形态并抑制子宫腺体发生。我们研究了经皮下注射10微升芝麻油给予结构相关抗雌激素托瑞米芬的交配期Sprague-Dawley大鼠雌性后代的子宫生长和分化情况,注射时间为出生后第(PND)1 - 5天、10 - 14天或20 - 24天。在子宫腺体快速分化的时期(PND 10 - 14)给予托瑞米芬,会导致子宫重量呈剂量相关增加,腔上皮细胞高度增加两倍,并且在剂量为10微克或更高时,在PND 14时完全抑制子宫腺体发育。基于此剂量反应分析,选择10微克剂量的托瑞米芬来评估新生儿暴露(PND 1 - 5)后的子宫发育情况。托瑞米芬使PND 5时的子宫重量和腔上皮细胞高度显著增加,但到PND 26时恢复到对照水平。PND 26时子宫腺体数量减少至对照的50%。在PND 20 - 24给予托瑞米芬的大鼠中也观察到剂量相关的子宫重量和腔上皮细胞高度增加。托瑞米芬的这种雌激素激动剂活性主要在子宫腔上皮中表现出来,表明托瑞米芬具有发育毒性。